Home
About
About Anagenics
Board of Directors
Divisions
Our Divisions
Beauty
Brands
évolis®
Uspa
Investors
Investor Centre
ASX Announcements
2024
2023
2022
2021
2020
2019
Financial Information & Reports
Share Registry Information
Analyst Coverage
Share Information
Anagenics in the media
Newsletter Archive
Corporate Governance
Corporate Governance
Board Charter
Code of Conduct
Policies
Audit Committee Charter
Nomination and Remuneration Committee Charter
Performance Evaluation Process
Corporate Code of Conduct
Environmental, Social and Governance Statement
✕
2015
Home
2015
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
US Patent for Anti-Midkine Antibodies Granted
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Change of Registry Address
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Final Director’s Interest Notice – G Kaufman
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Final Director’s Interest Notice – M Rogers
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Initial Director’s Interest Notice – B Gordon
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Dr Bryce Vissel to Chair Cellmid’s Scientific Advisory Board
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Cellmid Revenue Guidance Upgrade
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Transcript of Investor Conference Call
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Cellmid Appoints Dr Fintan Walton as Director
Prev page
1
2
3
4
5
6
Next page
